In-Med announces AI tool NeuroShield CT

Neuroshield CT promptly alerts neurologists to the presence of critical pathologies, offering quantifiable insights

In-Med AI announced the launch of ‘Neuroshield CT TBI.’ Neuroshield CT is an AI-based neurotrauma screening and quantification tool. Grounded in robust research and built on extensive imaging data, NeuroShield CT will aid neuro-critical teams in identifying and quantifying pathologies related to Traumatic Brain Injury (TBI) cases. Leveraging AI, NeuroShield CT automates manual image processing, ensuring accurate results on a timely basis. 


The state-of-the-art technology empowers radiologists, neurologists, and neurosurgeons with accurate data, facilitating rapid, informed decision-making around workflow prioritisation, acute triage management, and developing effective treatment plans in the case of neurotrauma. TBI is the primary cause of hospitalisation, disability, and post-injury mortality worldwide, often referred to as a ‘silent epidemic.’

Neuroshield CT promptly alerts neurologists to the presence of critical pathologies, offering quantifiable insights. NeuroShield CT provides crucial information, arming neurologists with the knowledge necessary for targeted interventions and improved patient outcomes. This tool is particularly essential for early intervention, a necessity during the “Golden Hour,” a critical post-trauma period. The software automatically detects and quantifies bleed (Intracranial Haemorrhage), fracture midline shift and Fracture.  

The product is integrated seamlessly into the clinical and radiology workflow and efficiently prioritises critical cases that require immediate attention. The reports are sent via the radiology information system, email, and phone to the concerned decision-makers. Further, radiologists are a scarce resource across the world and face a great deal of burnout due to the workload. AI-assisted automated tools can help reduce overload and reduce their burnout while helping the clinical teams focus their energies on the most critical cases in a timely fashion.

The algorithm’s development and training utilised data acquired through collaboration with world-class hospitals. This partnership proved highly beneficial, allowing engagement in collaborative research alongside expert doctors and neurosurgeons. 

Dr Deepak Agrawal, Professor Neurosurgery, AIIMS Trauma Centre, New Delhi, said, “We are delighted to partner with In-Med prognostics in developing a solution for automatic reading of Head CTs in traumatic brain injuries. Using this solution, patients can be automatically triaged for review by a neurosurgeon and patients with normal scans can be discharged without the intervention of radiologists or neurosurgeons. This is a distinctive technology with the potential to transform emergency care across the world.”

Dr Latha Poonamallee, Founder and CEO, In-Med said, “Every investment we make, every product we launch, and every technology we adopt and develop is guided by our mission to bring affordable, accessible, reliable, and state-of-the-art healthcare tools to everyone everywhere. Towards that end, we pride ourselves on being one of the most capital-efficient startups in our space. I am proud of our team that has developed this world-class product and look forward to continuing our trajectory onward.” 

This new product follows the pathbreaking Neuroshield MRI Volumetry product targeting neurodegenerative conditions like dementia, Alzheimer’s, Parkinson’s, and epilepsy. It is currently operational in over 280 sites in India, Africa, and the Middle East and recently received the US FDA 510 clearance for sales in the US market.


Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button